Suppr超能文献

微血管减压术作为两次等中心伽玛刀放射外科治疗失败的三叉神经痛患者的二线治疗。

Microvascular decompression as a second step treatment for trigeminal neuralgia in patients with failed two-isocentre gamma knife radiosurgery.

机构信息

Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Avenue No.1277, Wuhan, 430022, People's Republic of China.

出版信息

Neurosurg Rev. 2022 Feb;45(1):783-791. doi: 10.1007/s10143-021-01587-1. Epub 2021 Jul 22.

Abstract

OBJECTIVE

Subsequent microvascular decompression (MVD) might be affected by the previous two-isocentre gamma knife radiosurgery (GKS) due to the tissue changes caused by its higher dose radiation and larger treatment volume. This study aimed to evaluate the safety and efficacy of MVD as a second step treatment after two-isocentre GKS.

METHODS

Between December 2016 and May 2019, data from 19 consecutive trigeminal neuralgia (TN) patients who experienced MVD after failed two-isocentre GKS were collected. The clinical characteristics, intraoperative findings, surgical outcomes and complications were reviewed and compared with 158 patients who underwent MVD as an initial treatment.

RESULTS

Fifteen patients (78.9%) achieved complete pain relief (Barrow Neurological Institute, BNI class I) immediately after surgery and nine patients (47.4%) maintained complete pain relief at the last follow-up, which was similar to patients who underwent initial MVD. The median follow-up period was 36 months. The incidence of new or worsened facial numbness showed no statistical significance between the groups. During surgery, trigeminal nerve atrophy was noted in 9 patients (47.4%), thickened arachnoid in 3 patients (15.8%), atherosclerotic plaque in 3 patients (15.8%) and neurovascular adhesion in 1 patient (5.3%).

CONCLUSIONS

MVD remains an effective and safe rescue therapy for patients who elect the minimally invasive treatment with two-isocentre GKS for the first time, without an increased risk of facial numbness.

摘要

目的

由于两次等中心伽玛刀放射外科(GKS)较高剂量的辐射和较大的治疗体积导致的组织变化,随后的微血管减压(MVD)可能会受到影响。本研究旨在评估 MVD 作为两次等中心 GKS 治疗失败后的第二步治疗的安全性和有效性。

方法

在 2016 年 12 月至 2019 年 5 月期间,收集了 19 例因两次等中心 GKS 治疗失败而接受 MVD 治疗的三叉神经痛(TN)患者的临床资料。回顾分析了这些患者的临床特征、术中发现、手术结果和并发症,并与 158 例初次接受 MVD 治疗的患者进行了比较。

结果

15 例患者(78.9%)术后即刻达到完全疼痛缓解(巴罗神经研究所,BNI 分级 I),9 例患者(47.4%)在末次随访时保持完全疼痛缓解,与初次接受 MVD 治疗的患者相似。中位随访时间为 36 个月。两组患者新发或加重面部麻木的发生率无统计学意义。在手术过程中,9 例患者(47.4%)出现三叉神经萎缩,3 例患者(15.8%)蛛网膜增厚,3 例患者(15.8%)存在动脉粥样硬化斑块,1 例患者(5.3%)存在神经血管粘连。

结论

对于首次选择两次等中心 GKS 微创治疗的患者,MVD 仍然是一种有效且安全的挽救性治疗方法,不会增加面部麻木的风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验